Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study. Issue 3 (31st March 2016)

• Record Type: Journal Article
• Authors: Peyronnet, Benoit; Castel‐Lacanal, Evelyne; Roumiguie, Mathieu; Even, Lucie; Marque, Philippe; Soulié, Michel; Rischmann, Pascal; Game, Xavier
• Is Part Of: Neurourology and urodynamics. Volume 36:Issue 3(2017:Mar.)
• Page Start: 734
• Page End: 739
• Publication Date: 2016-03-31
• Subjects: abobotulinum toxin -- botulinum toxin -- detrusor overactivity -- neurogenic bladder -- onabotulinum toxin; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.23009
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract : Aims: To compare the outcomes of the first intradetrusor injections of abobotulinum toxin 750 U and onabotulinum toxin 200 and 300 U in patients with neurogenic detrusor overactivity (NDO). Methods: A retrospective case‐control study was conducted including 211 NDO patients treated in three consecutives eras with onabotulinum toxin 300 U (2004–2006; 80 patients), abobotulinum toxin 750 U (2007–2011; 78 patients) or onabotulinum toxin 200 U (2011–2014; 53 patients). Urodynamic and clinical parameters were compared between groups. The primary endpoint was the rates of success defined as the combination of urgency, urinary incontinence, and detrusor overactivity resolution. Results: When comparing abobotulinum toxin to onabotulinum toxin any doses (200 or 300 U; n = 133), success rates were similar (65.4% vs. 55.6%; P = 0.16). Patients treated with abobotulinum toxin 750 U had higher success rate (65.4% vs. 41.5%; P = 0.007) compared to those who received onabotulinum toxin 200 U. In contrast, there were similar success rates in abobotulinum toxin 750 U and onabotulinum toxin 300 U groups (65.4% vs. 65%; P = 0.91) but with a trend towards longer interval between the first and the second injection in the onabotulinum toxin 300 U group (12.4 vs. 9.3 months; P = 0.09). Conclusions: Intradetrusor injections of abobotulinum toxin 750 U for NDO provided better outcomes than injections of onabotulinum toxin 200 U. Success rates of abobotulinum toxin 750 U and onabotulinum toxin 300 U were similar but interval between injections tended to be longer with onabotulinum toxin 300 U. Neurourol. Urodynam. 36:734–739, 2017 . © 2016 Wiley Periodicals, Inc.